Table 2.

Adjusted ORs for association of trans-fatty acids with prostate cancer risk

2nd3rd4thP, trend
Monounsaturated, trans C16
    Δ9t 16:10.49 (0.31-0.79)*0.70 (0.45-1.10)0.71 (0.44-1.15)0.35
0.170.200.24
    Δ7t 16:10.72 (0.45-1.17)1.06 (0.66-1.71)0.98 (0.59-1.62)0.70
0.050.070.09
Monounsaturated, trans C18
    Δ8t 18:11.17 (0.75-1.84)1.13 (0.71-1.79)1.38 (0.86-2.22)0.22
0.150.200.26
    Δ9t 18:1(elaidic)1.05 (0.67-1.67)1.37 (0.86-2.17)1.39 (0.87-2.23)0.10
0.210.280.38
    Δ10t 18:11.03 (0.65-1.63)1.22 (0.77-1.94)1.41 (0.87-2.28)0.12
0.180.250.35
    Δ11t 18:1 (trans-vaccenic)1.14 (0.71-1.84)1.20 (0.73-1.97)1.69 (1.03-2.77)0.04
0.310.430.55
    Δ12t 18:11.15 (0.72-1.84)1.37 (0.86-2.20)1.53 (0.94-2.50)0.07
0.390.530.69
Diunsaturated, trans C18:2
    Δ9c,12t 18:21.69 (1.01-2.85)1.91 (1.14-3.18)1.79 (1.02-3.15)0.04
0.040.060.10
    Δ9t,12c 18:21.18 (0.74-1.89)1.12 (0.69-1.81)1.31 (0.80-2.12)0.35
0.100.130.17
    Δ9t,12t 18:20.98 (0.63-1.54)0.85 (0.54-1.34)1.19 (0.76-1.87)0.58
0.080.100.13
  • NOTE: Adjusted for exposure population, period of enrollment, enrollment center, enrollment age group, year of randomization, ethnicity, baseline smoking status, age at blood draw, BMI, alcohol use, and an indicator for sample selection.

  • * OR (95% confidence interval).

  • Lower bound quartile cutpoint (weight % of total fatty acids).